Abstract
Meeting abstracts Up to ~40 % of Hodgkin and non-Hodgkin lymphomas carry the Epstein-Barr virus (EBV) genome and express type 2 viral latency proteins (T2LPs) EBNA-1, LMP-1, LMP-2 and BARF-1. EBV specific T cells (EBVSTs) can be generated from the blood of EBV+ individuals, but are usually
Highlights
Up to ~40 % of Hodgkin and non-Hodgkin lymphomas carry the Epstein-Barr virus (EBV) genome and express type 2 viral latency proteins (T2LPs) EBNA-1, LMP-1, LMP-2 and BARF-1
EBV specific T cells (EBVSTs) can be generated from the blood of EBV+ individuals, but are usually dominated by T cells specific for viral proteins not expressed in type 2 latency lymphomas (T2LPs)
T2LP-specific EBVSTs could be generated from healthy-donors, we were unable to consistently generate EBVSTs with significant T2LP specificity from patients
Summary
Increasing the purity, potency and specificity of ebv-specific T cells to improve the treatment of EBV-positive lymphoma. Sandhya Sharma1*, Serena K Perna, Birju Mehta, Natalia Lapteva, Rayne Rouce, Carlos Ramos, Minhtran C Ngo, Vicky Torrano, Catherine M Bollard, Ann M Leen, Adrian P Gee, Helen Heslop, Cliona M Rooney. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
